MannKind

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MannKind reports strong Q4 earnings, eyes revenue growth opportunities

MannKind's strong financial performance in Q4 2022, driven by revenue growth and improved margins, positions the company for future success.
While challenges exist in healthcare innovation and regulatory processes, MannKind's focus on internal innovation and revenue diversification presents growth opportunities.
Opportunities in collaborations, inhaled therapeutics, and data-driven healthcare outcomes offer avenues for MannKind's future expansion and profitability.
Maintaining financial stability, driving revenue growth, and exploring new product opportunities are key strategies for MannKind's long-term success.

MannKind reports strong Q1 performance, eyes revenue growth opportunities

MannKind's Q1 2023 earnings call highlighted strong performance in royalty revenue, endocrine business, and liquidity position. Challenges include maintaining growth amidst competition, while opportunities lie in revenue growth and strategic collaborations. Overall, MannKind's positive outlook is supported by its pipeline progress and focus on shareholder value.

MannKind achieves first operating income, eyes international expansion for growth

MannKind's Q2 performance reflects significant financial milestones, with revenue growth, operating income, and strong gross margins showcasing operational efficiency and progress towards profitability.
While facing challenges such as trial costs and regulatory requirements, the company's strategic strengths in product expansion, R&D investments, and international partnerships position it for long-term growth.
Opportunities in strong patient demand, international market expansion, orphan lung areas, and product growth present avenues for revenue diversification and sustained performance.
Overall, MannKind's focus on innovation, financial sustainability, and market expansion sets a positive trajectory for future growth and profitability.

MannKind achieves first profitable quarter with strong revenue growth

MannKind's Q3 marked a profitable quarter with significant revenue growth and operational improvements.
Strengths include revenue diversification, margin enhancements, and promising trial progress.
Challenges lie in stabilizing V-Go revenue, fluctuating earnings, and trial design adjustments.
Opportunities include upcoming milestones, market leverage, and Medicare changes for growth.

MannKind reports record 2023 revenues, eyes growth opportunities in 2024

MannKind had a strong financial performance in 2023, with a focus on debt repayment, clinical trials, and shareholder value in 2024. Innovation in powders and NTM asset, along with strategic positioning and sales force optimization, offer growth potential.

MannKind reports record revenue in Q2 2024 earnings call

MannKind's Q2 2024 performance reflects strong revenue growth and progress on key products.
While facing challenges in IP protection and manufacturing capacity, the company maintains a healthy cash position.
Opportunities lie in upcoming milestones and market expansion, with a focus on enhancing financial performance.

MannKind reports record revenue, shifts focus to growth strategies

MannKind delivered strong financial performance, focusing on growth and innovation in its product portfolio. While transitioning Afrezza's mindset poses challenges, strategic investments and market expansion present promising opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, celebrated today that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics' Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso DPI represents the second FDA-approved product utilizing MannKind's innovative Technosphere® inhalation technology and is the first and only approved dry powder inhaled treatment for these indications.

MannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square.

MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products for people living with endocrine and orphan lung diseases, today announced that it has entered into an agreement with Zealand Pharma A/S (Nasdaq: ZEAL) to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.

MannKind Corporation Participating at Upcoming Conferences

MannKind Corporation (NASDAQ:MNKD ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Michael Castagna – Chief Executive Officer Steven Binder – Chief Financial Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Gregory Renza – RBC Capital Markets Thomas Smith – SVB Securities Bert Hazlett – BTIG Operator Good afternoon and welcome to the MannKind Corporation First Quarter 2022 Earnings Call. As a reminder, this call is being recorded on May 5, 2022, and will be available for playback on the MannKind Corporation's website shortly after the conclusion of this call until May 19, 2022.

MannKind Corporation (MNKD) CEO Michael Castagna on Q1 2022 Results - Earnings Call Transcript

Conference Call to Begin Today at 5:00 p.m. (ET) Conference Call to Begin Today at 5:00 p.m. (ET)

MannKind Corporation Reports 2022 First Quarter Financial Results

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Thursday, May 5, 2022.

MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022

WESTLAKE VILLAGE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has presented a poster [Abstract #445] at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) held April 27-30 in Barcelona and virtually. The poster is now available to meeting attendees online.

MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30

DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

DANBURY, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas Hofmann, MD, PhD, will participate in the Cantor Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 8:00 am (PT).

MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

DANBURY, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a virtual presentation at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:00 pm (ET).

MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference

MannKind's (MNKD) CEO Michael Castagna on Q4 2021 Results - Earnings Call Transcript

Conference Call to Begin Today at 5:00 p.m. (ET)

MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S. Food and Drug Administration (FDA) issued an information request to United Therapeutics Corporation earlier this month regarding the New Drug Application (NDA) for Tyvaso DPI, requesting additional information regarding the pulmonary safety of Tyvaso DPI related to a pending Citizen Petition. United Therapeutics promptly responded to the agency's request. MannKind has now learned that the FDA considers the response to be a major amendment to the NDA, thereby extending to May 2022 the FDA's deadline to complete its review of the pending NDA.

Update on Tyvaso DPI™ New Drug Application

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00 p.m. (Eastern Time) on Thursday, February 24, 2022.

MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022

Ambev

New Gold

Southwestern Energy

TC Biopharm Holdings PLC

5 must watch penny stocks that you should know about in February The post 5 ‘Must Watch' Penny Stocks For February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 ‘Must Watch' Penny Stocks For February 2022

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 pm (ET).

MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference

Eyenovia

loanDepot

Oncternal Therapeutics Inc

Performant Financial

P3 Health Partners Inc

Pixelworks

Vaccinex Inc

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks To Buy Now According To Insiders In 2022

MannKind's Afrezza is the only FDA-approved ultra-rapid-acting inhalable insulin for adults with diabetes, a major lifestyle disease affecting 1 in 10 Americans.

MannKind: A Promising Player In The Inhalable Insulin Market

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. (“Thirona”) with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the Company's Chief Executive Officer, Michael Castagna, PharmD, will be participating in a webcasted Fireside Chat discussing its vision for 2022 and Mr. Castagna and the Company's Chief Financial Officer, Steven B. Binder will be conducting 1x1 virtual investor meetings.

MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2021 Results - Earnings Call Transcript

MannKind (NASDAQ:MNKD) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Recap: MannKind Q3 Earnings

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8, 2021, of its previously announced sale-leaseback transaction with an affiliate of Creative Manufacturing Properties. The transaction results in $102.25 million in non-dilutive gross proceeds to MannKind. Simultaneous with closing of the purchase and sale agreement, MannKind entered into a 20-year lease agreement with the purchaser, with multiple renewal options available.

News for MannKind Stock (MNKD)